Rafferty Asset Management’s ArriVent BioPharma AVBP Stock Holding History

Rafferty Asset Management’s Portfolio AVBP Stock Details AVBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$847K	Sell	24,380 -12,873	-35%	-$380K	﹤0.01%	818
2026 Q1	$859K	Buy	37,253 +8,375	+29%	+$189K	﹤0.01%	808
2025 Q4	$581K	Sell	28,878 -5,483	-16%	-$114K	﹤0.01%	884
2025 Q3	$634K	Buy	34,361 +18,612	+118%	+$366K	﹤0.01%	870
2025 Q2	$343K	Sell	15,749 -1,660	-10%	-$34.5K	﹤0.01%	955
2025 Q1	$322K	Sell	17,409 -9,890	-36%	-$242K	﹤0.01%	946
2024 Q4	$727K	Buy	27,299 +17,763	+186%	+$510K	﹤0.01%	847
2024 Q3	$224K	Buy	+9,536	New	+$216K	﹤0.01%	1083

Other funds holding AVBP

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

IAM

Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Rafferty Asset Management's AVBP Position: Q2 2026 in Review

Rafferty Asset Management reduced its ArriVent BioPharma (AVBP) stake by 35% in Q2 2026, selling an estimated $380K and leaving 24,380 shares worth $847K. The position accounts for ﹤0.01% of the portfolio, ranked #818.

Rafferty Asset Management first reported a position in AVBP in Q3 2024 and has held it in 8 quarters since. The position peaked at $859K in Q1 2026. 158 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

Rafferty Asset Management held 24,380 shares of ArriVent BioPharma worth $847K as of Q2 2026.
Rafferty Asset Management sold 12,873 ArriVent BioPharma shares in Q2 2026, an estimated $380K.
ArriVent BioPharma made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #818 holding.
Rafferty Asset Management first reported a position in ArriVent BioPharma in Q3 2024 and has held it in 8 quarters since.
Rafferty Asset Management's ArriVent BioPharma position peaked at $859K in Q1 2026.
158 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.